KLOW: Research, Handling and Batch Documentation

Identity and research status

Product Type

Multi-peptide combination vial, not a single chemical entity

Stated Constituents

GHK or GHK-Cu, KPV, BPC-157 and TB-500

Total Peptide Mass

80mg per vial

Constituent Ratio

Not disclosed on the product listing

Relationship to GLOW

GLOW with KPV added, which is what the name records

CAS Number

Not applicable. A mixture has no single CAS number

KPV Component

Tripeptide Lys-Pro-Val, 342.44 g/mol

GHK-Cu Component

Gly-His-Lys with copper(II), near 401 to 403 g/mol

BPC-157 Component

15 amino acids, GEPPPGKPADDAGLV, 1419.53 g/mol

TB-500 Component

Acetylated heptapeptide Ac-LKKTETQ, 889.02 g/mol

Mechanism, in brief

KLOW is a combination vial rather than a single molecule. The catalogue's own tools data names it as GHK, KPV, BPC-157 and TB-500 supplied together, which is GLOW with KPV added, and the name records that origin. Four constituents means four unrelated mechanisms occurring in one vial, not a single blend mechanism.

1. KPV: transporter-mediated anti-inflammatory action. Enters cells through the PepT1 oligopeptide transporter, which is upregulated in inflamed tissue, and suppresses pro-inflammatory signalling including NF-kappaB activation.
2. GHK-Cu: copper delivery. Carries copper(II) to enzymes requiring it as a cofactor, including lysyl oxidase, which cross-links collagen and elastin during matrix maturation.
3. BPC-157: angiogenic and nitric oxide interactions. Reported upregulation of VEGFR2 signalling and modulation of nitric oxide pathways, without any identified receptor.
4. TB-500: actin sequestration. The LKKTET motif binds monomeric G-actin, influencing filament assembly and cell migration.
5. Untested as a combination. No controlled study has evaluated these four together, so additivity, interaction and interference between them are all unmeasured.

The full research write-up, including the findings behind each claim and the model each came from, is on the KLOW 80mg 80mg page.

Vial sizes available

Every size of KLOW Volta lists, in stock or not. Each is a separate catalogue page with its own batch number and specification table.

• 

  KLOW 80mg 80mgBatch #: VPKL80100
  In stock

Purity and batch documentation

Volta's release specification is >99% (HPLC). That is a threshold we set. >99% is the specification every batch is released to. The figure on a certificate is what a laboratory measured for one lot.

• SideChain Analytics reported 99.74% average across 4 measured components (BPC-157 99.59%, TB-500 99.62%, GHK-Cu 99.81%, KPV 99.64%) by HPLC-MS/MS on September 27, 2026, lot VPKL80100.

  Covers the KLOW 80mg vial.

  Read the certificateVerify on lab's website (Verify on SideChain Analytics's website, opens in a new tab)

Handling and stability

Regulatory context

• the legal status of research peptides in Canada
• Health Canada's regulatory position

Primary sources

1. Kannengiesser K, Maaser C, Heidemann J, et al.. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases (2008). PMID 18092346
2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al.. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). PMID 18061177
3. Maquart FX, Bellon G, Chaqour B, et al.. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation (1993). PMID 8227353
4. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition (2008). PMID 18644225
5. Seiwerth S, Milavic M, Vukojevic J, et al.. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology (2021). PMID 34267654
6. Bock-Marquette I, Saxena A, White MD, et al.. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature (2004). PMID 15565145
7. Mendias CL, Awan TM, et al.. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries. Sports Medicine (2026). PMID 41966639